Donna Berry on Prostate Cancer Patients' Challenges

Stereotactic ablative body radiotherapy in primary renal cell cancer may be a treatment approach with an acceptable adverse effect profile and with minimal impact on renal function.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Overall, the transition from breast to genitourinary cancer has added depth and dimension to my knowledge of cancer care.

In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.

Olaparib improved survival outcomes in all assessed subgroups of patients with BRCA-altered metastatic castration-resistant prostate cancer.

The FDA has approved belzutifan to treat patients with advanced renal cell carcinoma (RCC) who have already undergone PD-1 or PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.